Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen (PREMIER) trial design

Subhash Banerjee, Mazen Abu Fadel, Ravi Sarode, Lance Terada, Thomas Moritz, Ping Luo, Jeffrey Hastings, Emmanouil S. Brilakis, Domenic Reda

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Progression of lipid rich necrotic core elements of atherosclerotic vulnerable plaque (VP) or its rupture leads to a majority of cardiovascular events. Endothelial progenitor cells (EPC) contribute to vascular healing and play a crucial role in repair following ischemic injury primarily by endothelialization of VP and neovascularization of ischemic myocardium. We present the rationale and design of the Plaque Regression and Progenitor Cell Mobilization with Intensive Lipid Elimination Regimen or the PREMIER Trial, which is designed to address the question for the very first time whether a highly intensive low-density lipoprotein (LDL)-lowering therapy with LDL-apheresis could lead to a more rapid and detectable reduction in coronary atheroma volume, along with a robust mobilization of EPC compared to standard statin therapy, in patients selected for percutaneous coronary intervention for an acute coronary syndrome. J. Clin. Apheresis 29:97-106, 2014. © 2013 Wiley Periodicals, Inc.

Original languageEnglish (US)
Pages (from-to)97-106
Number of pages10
JournalJournal of Clinical Apheresis
Volume29
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Blood Component Removal
Stem Cells
Atherosclerotic Plaques
Lipids
LDL Lipoproteins
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Percutaneous Coronary Intervention
Acute Coronary Syndrome
Blood Vessels
Rupture
Myocardium
Wounds and Injuries
Therapeutics
Endothelial Progenitor Cells

Keywords

  • atherosclerosis
  • endothelial progenitor cell (EPC)
  • hyperlipidemia
  • low-density lipoprotein (LDL) apheresis

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

@article{5d61f394ae5b4f62bb341ffb111ed485,
title = "Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen (PREMIER) trial design",
abstract = "Progression of lipid rich necrotic core elements of atherosclerotic vulnerable plaque (VP) or its rupture leads to a majority of cardiovascular events. Endothelial progenitor cells (EPC) contribute to vascular healing and play a crucial role in repair following ischemic injury primarily by endothelialization of VP and neovascularization of ischemic myocardium. We present the rationale and design of the Plaque Regression and Progenitor Cell Mobilization with Intensive Lipid Elimination Regimen or the PREMIER Trial, which is designed to address the question for the very first time whether a highly intensive low-density lipoprotein (LDL)-lowering therapy with LDL-apheresis could lead to a more rapid and detectable reduction in coronary atheroma volume, along with a robust mobilization of EPC compared to standard statin therapy, in patients selected for percutaneous coronary intervention for an acute coronary syndrome. J. Clin. Apheresis 29:97-106, 2014. {\circledC} 2013 Wiley Periodicals, Inc.",
keywords = "atherosclerosis, endothelial progenitor cell (EPC), hyperlipidemia, low-density lipoprotein (LDL) apheresis",
author = "Subhash Banerjee and {Abu Fadel}, Mazen and Ravi Sarode and Lance Terada and Thomas Moritz and Ping Luo and Jeffrey Hastings and Brilakis, {Emmanouil S.} and Domenic Reda",
year = "2014",
doi = "10.1002/jca.21298",
language = "English (US)",
volume = "29",
pages = "97--106",
journal = "Journal of Clinical Apheresis",
issn = "0733-2459",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen (PREMIER) trial design

AU - Banerjee, Subhash

AU - Abu Fadel, Mazen

AU - Sarode, Ravi

AU - Terada, Lance

AU - Moritz, Thomas

AU - Luo, Ping

AU - Hastings, Jeffrey

AU - Brilakis, Emmanouil S.

AU - Reda, Domenic

PY - 2014

Y1 - 2014

N2 - Progression of lipid rich necrotic core elements of atherosclerotic vulnerable plaque (VP) or its rupture leads to a majority of cardiovascular events. Endothelial progenitor cells (EPC) contribute to vascular healing and play a crucial role in repair following ischemic injury primarily by endothelialization of VP and neovascularization of ischemic myocardium. We present the rationale and design of the Plaque Regression and Progenitor Cell Mobilization with Intensive Lipid Elimination Regimen or the PREMIER Trial, which is designed to address the question for the very first time whether a highly intensive low-density lipoprotein (LDL)-lowering therapy with LDL-apheresis could lead to a more rapid and detectable reduction in coronary atheroma volume, along with a robust mobilization of EPC compared to standard statin therapy, in patients selected for percutaneous coronary intervention for an acute coronary syndrome. J. Clin. Apheresis 29:97-106, 2014. © 2013 Wiley Periodicals, Inc.

AB - Progression of lipid rich necrotic core elements of atherosclerotic vulnerable plaque (VP) or its rupture leads to a majority of cardiovascular events. Endothelial progenitor cells (EPC) contribute to vascular healing and play a crucial role in repair following ischemic injury primarily by endothelialization of VP and neovascularization of ischemic myocardium. We present the rationale and design of the Plaque Regression and Progenitor Cell Mobilization with Intensive Lipid Elimination Regimen or the PREMIER Trial, which is designed to address the question for the very first time whether a highly intensive low-density lipoprotein (LDL)-lowering therapy with LDL-apheresis could lead to a more rapid and detectable reduction in coronary atheroma volume, along with a robust mobilization of EPC compared to standard statin therapy, in patients selected for percutaneous coronary intervention for an acute coronary syndrome. J. Clin. Apheresis 29:97-106, 2014. © 2013 Wiley Periodicals, Inc.

KW - atherosclerosis

KW - endothelial progenitor cell (EPC)

KW - hyperlipidemia

KW - low-density lipoprotein (LDL) apheresis

UR - http://www.scopus.com/inward/record.url?scp=84898824300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898824300&partnerID=8YFLogxK

U2 - 10.1002/jca.21298

DO - 10.1002/jca.21298

M3 - Article

VL - 29

SP - 97

EP - 106

JO - Journal of Clinical Apheresis

JF - Journal of Clinical Apheresis

SN - 0733-2459

IS - 2

ER -